First Clinical Study with Elanix’ Progenitor Cells

08.08.2017 17:23

Related tags

Study

Elanix announced today the treatment of the first patient in a Phase I/II clinical trial with TWB-103 in adults with skin graft donor site wounds. The study is being conducted in Taiwan and Japan with partner Transwell Biotech. TWB-103 is a novel gel formulation developed by Transwell Biotech, using skin fibroblast progenitor cells provided by Elanix.

Elanix  develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.

 “The start of the first human studies of TWB-103 is a significant milestone in our plan to build a regenerative medicine franchise in acute wound healing based on our proprietary progenitor cell technology. This gets us one step closer to introducing an acute wound care treatment to the market which could benefit over two million patients worldwide that are hospitalised for burns annually,” stated Tomas Svoboda, CEO of Elanix Biotechnologies. “The team at Transwell has been very efficient in advancing a solid clinical strategy in Asia."

“TWB-103 is a key part of our future wound-care pipeline. The first patient has now been treated and this clinical milestone is a major step for Transwell Biotech and one that we intend to expand to other Asian markets this year,” said Dr. Sean Chen, General Manager of Transwell Biotech.

The study will be conducted at the Tri-Service General Hospital in Taipei as well as the Tokyo Medical University Hospital and the Nippon Medical School Hospital in Tokyo. The aim is to compare safety and efficacy of TWB-103 with standard of care Tegaderm skin dressing to Tegaderm alone in 30 individuals. Primary objectives are safety and healing time from DSW creation to 100% re-epithelialization.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.